Laura Iadeluca

590 total citations · 1 hit paper
24 papers, 381 citations indexed

About

Laura Iadeluca is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Laura Iadeluca has authored 24 papers receiving a total of 381 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 5 papers in Reproductive Medicine. Recurrent topics in Laura Iadeluca's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Lung Cancer Research Studies (7 papers). Laura Iadeluca is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Lung Cancer Research Studies (7 papers). Laura Iadeluca collaborates with scholars based in United States, Japan and Italy. Laura Iadeluca's co-authors include Geoffrey Makinson, Markay Hopps, Margaret V. McDonald, Geoffrey Liu, Enriqueta Felip, Todd M. Bauer, Julien Mazières, Tony Mok, Filippo de Marinis and Benjamin Solomon and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Gynecologic Oncology.

In The Last Decade

Laura Iadeluca

21 papers receiving 368 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

2022 129 citations Benjamin Solomon, Todd M. Bauer et al. The Lancet Respiratory Medicine profile →

Peers

Countries citing papers authored by Laura Iadeluca

Since Specialization

Citations

This map shows the geographic impact of Laura Iadeluca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Iadeluca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Iadeluca more than expected).

Fields of papers citing papers by Laura Iadeluca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Iadeluca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Iadeluca. The network helps show where Laura Iadeluca may publish in the future.

Co-authorship network of co-authors of Laura Iadeluca

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Iadeluca. A scholar is included among the top collaborators of Laura Iadeluca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Iadeluca. Laura Iadeluca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis 2025 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Susan C. Locke, (unknown), Jesse D. Troy, (unknown), (unknown), (unknown), Laura Iadeluca, (unknown), Cristina Gasparetto, Mark Newman, Thomas W. LeBlanc	0
2	PARP inhibitors and maintenance treatment decision-making in advanced ovarian cancer: Patient and clinician perspectives 2024 ·Gynecologic Oncology ·Ashley Haggerty, Amy Barrett, Jennifer Dine, Laura Iadeluca, Anna Jo Bodurtha Smith, (unknown)	1
3	Real‐world study of next‐generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan 2023 ·Cancer Science ·Toshiaki Takahashi, Makoto Nishio, Kazumi Nishino, (unknown), (unknown), Birol Emir, Laura Iadeluca, Yasushi Yatabe, Kazuto Nishio	11
4	Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden 2023 ·Applied Health Economics and Health Policy ·(unknown), (unknown), Fredrik Nilsson, Laura Iadeluca, (unknown)	10
5	PARPi monotherapy as first-line maintenance following chemotherapy + bevacizumab in advanced ovarian cancer. 2023 ·Journal of Clinical Oncology ·Fred J. Kudrik, Anupama Vasudevan, (unknown), (unknown), (unknown), John Hartman, Laura Iadeluca	1
6	Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer 2023 ·Future Oncology ·Benjamin Solomon, Todd M. Bauer, Tony Mok, Geoffrey Liu, Julien Mazières, Filippo de Marinis, Yasushi Goto, Dong‐Wan Kim, Yi‐Long Wu, Jacek Jassem, (unknown), Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip	0
7	Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study breakdown → 2022 ·The Lancet Respiratory Medicine ·Benjamin Solomon, Todd M. Bauer, Tony Mok, Geoffrey Liu, Julien Mazières, Filippo de Marinis, Yasushi Goto, Dong‐Wan Kim, Yi‐Long Wu, Jacek Jassem, (unknown), Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip	129
8	Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer 2022 ·Value in Health ·Sarah Smith, (unknown), (unknown), Laura Iadeluca, (unknown)	4
9	Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer 2022 ·Lung Cancer ·Julien Mazières, Laura Iadeluca, Alice T. Shaw, Benjamin Solomon, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Dong‐Wan Kim, Tony Mok, Arlene Reisman, Holger Thurm, Anna Polli, Geoffrey Liu	23
10	Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC 2022 ·JTO Clinical and Research Reports ·Yi‐Long Wu, Shun Lü, James Chih‐Hsin Yang, Jianying Zhou, Takashi Seto, Myung‐Ju Ahn, Wu‐Chou Su, Noboru Yamamoto, Dong‐Wan Kim, Jolanda Paolini, Tiziana Usari, Laura Iadeluca, Keith D. Wilner, Kōichi Goto	12
11	The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden 2021 ·PharmacoEconomics ·Fredrik Nilsson, (unknown), Elizabeth T. Masters, Laura Iadeluca, (unknown), (unknown), Sarah Smith	8
12	Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study 2021 ·Targeted Oncology ·David Waterhouse, Laura Iadeluca, (unknown), Keith D. Wilner, Birol Emir, Stan Krulewicz, Janet L. Espirito, (unknown)	10
13	MA11.08 Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC 2021 ·Journal of Thoracic Oncology ·Julien Mazières, Laura Iadeluca, Alice T. Shaw, Benjamin Solomon, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, D. Kim, Tony Mok, Arlene Reisman, Holger Thurm, Anna Polli, (unknown)	2
14	Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan 2020 ·JTO Clinical and Research Reports ·Yasushi Yatabe, (unknown), Koichi Matsumura, Kanae Togo, Hironori Kikkawa, Laura Iadeluca, Benjamin Li, Kazuto Nishio	9
15	PCN6 Matching-Adjusted Indirect Treatment Comparisons (MAIC) of the Effect of Lorlatinib Versus Chemotherapy on Overall Survival (OS) and Progression-Free Survival (PFS) for Patients with Second-LINE or Later Anaplastic Lymphoma Kinase (ALK)-Positive NON-SMALL CELL LUNG Cancer (NSCLC) 2020 ·Value in Health ·(unknown), (unknown), (unknown), Laura Iadeluca, (unknown)	2
16	PCN1 Incremental Effectiveness of Crizotinib for Treating ROS1-Positive Advanced NON-SMALL-CELL LUNG Cancer in Portugal 2020 ·Value in Health ·(unknown), Albert E. Hirst, Laura Iadeluca, (unknown), (unknown)	2
17	PCN284 PSYCHOMETRIC EVALUATION AND SCORE INTERPRETATION OF THE NCCN-FACT OVARIAN SYMPTOM INDEX-18 IN PATIENTS WITH ADVANCED OVARIAN CANCER: REAL-WORLD EVIDENCE 2019 ·Value in Health ·Andrew Trigg, Mark Kelly, Laura Iadeluca, Jane Chang, (unknown), Andrew Yaworsky, Meaghan Krohe, A. Rider, J.C. Cappelleri, David Cella, Kim Cocks	1
18	Maternal Screening And Treatment For Group B Streptococcus (GBS) Are Associated With Non-Adherence To Guidelines, False-Negative Results And High Management Costs In The United Kingdom, Italy, France, Spain And Germany 2017 ·Value in Health ·Laura Iadeluca, Emily Farrington, (unknown), (unknown), (unknown), Judith Absalon, (unknown)	2
19	The burden of family caregiving in the United States: work productivity, health care resource utilization, and mental health among employed adults 2017 ·Journal of Multidisciplinary Healthcare ·Markay Hopps, Laura Iadeluca, Margaret V. McDonald, Geoffrey Makinson	92
20	The burden of selected cancers in the US: health behaviors and health care resource utilization 2017 ·Cancer Management and Research ·Laura Iadeluca, Jack Mardekian, (unknown), Markay Hopps, Geoffrey Makinson	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact